Olmesartan

• CAT Number: I001723
• CAS Number: 144689-24-7
• Molecular Formula: C24H26N6O3
• Molecular Weight: 446.5
• Purity: ≥95%
• Target: Angiotensin Receptor
• Solubility: DMSO: ≥ 55 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 5-(2-hydroxypropan-2-yl)-2-propyl-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazole-4-carboxylic acid
• InChI: InChI=1S/C24H26N6O3/c1-4-7-19-25-21(24(2,3)33)20(23(31)32)30(19)14-15-10-12-16(13-11-15)17-8-5-6-9-18(17)22-26-28-29-27-22/h5-6,8-13,33H,4,7,14H2,1-3H3,(H,31,32)(H,26,27,28,29)
• InChIKey: VTRAEEWXHOVJFV-UHFFFAOYSA-N
• SMILES: O=C(C1=C(C(C)(O)C)N=C(CCC)N1CC2=CC=C(C3=CC=CC=C3C4=NN=NN4)C=C2)O

Olmesartan (Cat.No:I001723) is an angiotensin II receptor blocker (ARB) used to treat hypertension. By blocking the angiotensin II receptor, Olmesartan helps relax and widen blood vessels, reducing blood pressure. It is often prescribed as a monotherapy or in combination with other antihypertensive medications. Olmesartan is well-tolerated and has shown efficacy in managing hypertension in clinical settings.

Reference

1:Antihypertensive drugs aliskiren, nebivolol, and olmesartan reduce hypertension by reducing endothelial microparticle and regulating angiogenesis. Jain M, Bhosale V, Tripathi D, Singh H, Pal N, Hanif K, Jagavelu K.J Cardiovasc Pharmacol. 2017 May 9. doi: 10.1097/FJC.0000000000000503. [Epub ahead of print] PMID: 28498232 2:Comparison of Efficacy and Safety of Azilsartan and Olmesartan in Patients With Essential Hypertension. Shiga Y, Miura SI, Motozato K, Norimatsu K, Yano M, Hitaka Y, Adachi S, Kuwano T, Inoue K, Inoue A, Fujisawa K, Shirotani T, Kusumoto T, Ideishi M, Saku K.Int Heart J. 2017 May 12. doi: 10.1536/ihj.16-285. [Epub ahead of print] PMID: 28496022 Free Article3:Efficacy of olmesartan amlodipine in Colombian hypertensive patients (soat study). Buendia R, Zambrano M.BMC Res Notes. 2017 Apr 26;10(1):164. doi: 10.1186/s13104-017-2486-z. PMID: 28441972 Free PMC Article4:Autoimmune-like chronic hepatitis induced by olmesartan. Barge S, Ziol M, Nault JC.Hepatology. 2017 Apr 24. doi: 10.1002/hep.29228. [Epub ahead of print] PMID: 28437842 5:Olmesartan. Al-Majed AA, Bakheit AHH, Abdel Aziz HA, Al-Jallal AAM.Profiles Drug Subst Excip Relat Methodol. 2017;42:241-286. doi: 10.1016/bs.podrm.2017.02.005. Epub 2017 Mar 31. PMID: 28431778 6:Pharmacovigilance database search discloses ClC-K channels as a novel target of the AT1 receptor blockers valsartan and olmesartan. Imbrici P, Tricarico D, Mangiatordi GF, Nicolotti O, Lograno MD, Conte D, Liantonio A.Br J Pharmacol. 2017 Mar 23. doi: 10.1111/bph.13794. [Epub ahead of print] PMID: 28334417 7:miR-205 mediates the inhibition of cervical cancer cell proliferation using olmesartan. Yue Z, Yun-Shan Z, Feng-Xia X.J Renin Angiotensin Aldosterone Syst. 2016 Jul-Sep;17(3):1470320316663327. doi: 10.1177/1470320316663327. PMID: 28304186 8:Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects. Mandraffino G, Aragona CO, Cairo V, Scuruchi M, Lo Gullo A, D/’Ascola A, Alibrandi A, Loddo S, Quartuccio S, Morace C, Mormina E, Basile G, Saitta A, Imbalzano E.PLoS One. 2017 Mar 16;12(3):e0173030. doi: 10.1371/journal.pone.0173030. eCollection 2017. PMID: 28301500 Free PMC Article9:Olmesartan-associated sprue-like enteropathy: An emerging cause of drug-induced chronic diarrhea. Solano-Iturri G, García-Jiménez N, Solano-Iturri JD, Blanco-Sampascual S.Rev Gastroenterol Mex. 2017 Mar 10. pii: S0375-0906(17)30011-3. doi: 10.1016/j.rgmx.2016.06.006. [Epub ahead of print] English, Spanish. No abstract available. PMID: 28291561 Free Article10:Development of olmesartan medoxomil lipid-based nanoparticles and nanosuspension: preparation, characterization and comparative pharmacokinetic evaluation. B A, D N, Veerabrahma K.Artif Cells Nanomed Biotechnol. 2017 Mar 14:1-12. doi: 10.1080/21691401.2017.1299160. [Epub ahead of print] PMID: 28290712